Statement on continued progress enhancing patient access to high-quality, low-cost generic drugsOctober 16, 2019
FDA approves first treatment to increase pain-free light exposure in patients with a rare disorderOctober 8, 2019
FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseasesOctober 8, 2019
Statement on consumer warning to stop using THC vaping products amid ongoing investigation into lung illnessesOctober 4, 2019
FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemicOctober 3, 2019
FDA informs patients, providers and manufacturers about potential cybersecurity vulnerabilities for connected medical devices and health care networks that use certain communication softwareOctober 1, 2019
Statement on measuring the progress being made through implementing the FDA Food Safety Modernization ActSeptember 30, 2019
Statement on continued efforts to evaluate materials in medical devices to address potential safety questionsSeptember 30, 2019
FDA approves first treatment for children with rare diseases that cause inflammation of small blood vesselsSeptember 27, 2019
FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeksSeptember 26, 2019
Statement on new steps to advance digital health policies that encourage innovation and enable efficient and modern regulatory oversightSeptember 26, 2019
Remarks prepared for testimony before a U.S. House Energy and Commerce Subcommittee on FDA Regulation of Electronic Nicotine Delivery Systems and Investigation of Vaping IllnessesSeptember 25, 2019
FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impuritySeptember 24, 2019
Statement on FDA efforts to encourage patient engagement in medical device clinical investigationsSeptember 23, 2019
